Lung cancer, breast cancer
Conditions
Interventions
EN group:N/A
PN group:N/A
Nutrition advisory group:N/A
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ?adult patients with unresectable locally advanced or metastatic lung or breast cancer diagnosed by histopathology and/or cytology; ?AJCC stage III or IV; ?having at least one measurable lesion confirmed by CT or MRI according to RECIST 1.1 criteria for assessing the objective efficacy of oncologic therapy. Target lesions located within the irradiated field of previous radiotherapy or within the area after local treatment were considered measurable if progression was confirmed; ? the presence of nutritional risk as assessed by NRS2002 or malnutrition as assessed by PG-SGA; ? expected survival = 3 months; ? planned to continue chemotherapy at our hospital for = 3 subsequent cycles (both surgical and non-surgical patients); ? patients and their families were informed of this study and signed Informed consent form
Exclusion criteria
Exclusion criteria: (1) Patients with double primary or multiple primary malignancies; (2) Patients without pathological confirmation; (3) Patients with severe cardiac, hepatic, or renal dysfunction or other life-threatening comorbidities; (4) Patients who did not cooperate with this study, withdrew from the manager midway, or were unable/unwilling to complete the follow-up program; (5) Patients with communication disorders or psychiatric disorders; (6) Patients who had received parenteral or enteral nutrition therapy prior to admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate;disease control rate;the QLQ-C30 score; | — |
Secondary
| Measure | Time frame |
|---|---|
| body mass;body mass index;total protein;arm circumference;Triceps skin fold thickness;albumin;hemoglobin;IgG;IgA;CD4+/CD8+;hypersensitive C-reactive protein;tumor necrosis factor a;prealbumin;NRS2002 score;PG-SGA score;CD4+ T-lymphocytes;CD8+ T-lymphocytes;IL-2;IL-4;IL-6;IL-10;adverse reaction rate; | — |
Countries
China
Contacts
Public ContactChen Shi
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
Outcome results
None listed